The Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings for hospitals and ambulatory care settings comprises drugs that can be administered via various parenteral routes including intravenous, intramuscular, and subcutaneous injections. The market mainly consists of medications for cardiovascular diseases, cancer, pain management, infectious diseases, and respiratory conditions. Self-injectable drugs are gaining popularity in Brazil as they allow patients to administer therapies independently. The growing prevalence of chronic diseases and increasing healthcare expenditure in the country are also fueling demand for injectable medications.
The Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings is estimated to be valued at US$ 10775 Mn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The increasing demand for self-injectable drugs is one of the major drivers of the Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings for hospitals and ambulatory care settings. Self-administration allows patients to conveniently receive treatments at home and avoid visits to healthcare facilities. This is particularly beneficial for individuals suffering from chronic conditions who require frequent drug administration. Moreover, self-injectable drugs empower patients by giving them more control over their medical treatment.
The growing prevalence of chronic diseases such as diabetes, cancer, and autoimmune disorders is also fueling market growth. According to the estimates by Health Ministry, nearly 15 million people in Brazil have diabetes, which is one of the leading causes of mortality. Furthermore, coronary heart disease and stroke together account for over 30% of total annual deaths in the country. Rising chronic disease burden has significantly increased the demand for various injectable drugs in Brazil over the past few years.
SWOT Analysis
Strength: The Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings has a large patient pool owing to growing aging population and rising healthcare expenditures. This further boosts the demand for injectable drugs. Rapid urbanization and rising awareness about chronic diseases also drive market growth.
Weakness: High costs associated with manufacturing injectable drugs as stringent sterilization process. Limited reimbursement policies restrict the adoption of advanced and high-priced injectable drugs in Brazil. Lack of healthcare infrastructure in rural areas poses a challenge.
Opportunity: Untapped opportunities exist in developing specialized drugs for Latin American countries like Brazil. Rise in self-administration trends offer scope for single-dose prefilled syringes. Collaboration with regional healthcare providers help penetrate tier-2 and tier-3 cities.
Threats: Stringent regulatory norms for approval delays market entry of novel drugs. Increasing prices of Active Pharmaceutical Ingredients (APIs) elevates production costs. Patent cliffs of major drugs intensify competition.
Key Takeaways
The Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings Share is expected to witness high growth owing to rising prevalence of chronic diseases and growing medical needs of aging population in Brazil. The market size was valued at US$ 10775 million in 2024 and is estimated to surpass US$ 20,000 million by 2031, registering a CAGR of 7.8% during the forecast period.
Regional analysis: The southeast region dominates the Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings and is growing at over 8% Y-o-Y owing to presence of leading pharmaceutical companies and availability of advanced healthcare facilities across major cities like Sao Paolo and Rio de Janeiro. States like Minas Gerais and Parana are other high potential markets offering lucrative opportunities.
Key players: Key players operating in the Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings are Pfizer, Novartis, Baxter, Sanofi, GlaxoSmithKline. These players are focusing on new product launches, collaborations with local hospitals, and strategic partnerships to strengthen market presence and cater wider patient pool across Brazil.
Get More Insights Here
https://whotimes.com/hashgraph-the-next-generation-distributed-ledger-technology/
https://www.newswirestats.com/brazil-injectable-drugs-market-for-hospitals-ambulatory-settings/
The Spirulina Market is expected to grow at a CAGR of 10.3% from 2020-2030, according to a new research report by Next Move Strategy ConsultingSpirulina is a blue green algae with high nutrient content, usually consumed by human & animals.
It is also used as a complementary diet ingredient in aquaculture & poultry feeds owing to the presence of high protein & vitamin content.According to the report, growth in health consciousness among people and the rising demand for dietary supplements are major factors driving the spirulina market growth.
Additionally, high penetration of spirulina in industries such as cosmetics and pharmaceutical owing to the advantageous properties such as anti-aging, anti-wrinkles and othersare bringing changes in market tends.However, low stability & poor sustainability of spirulina derived colours is expected to restrict the market growth.Moreover, growth in research & development activities followed by untapped market opportunities in developing economies are anticipated to provide numerous opportunities to the market players in the coming few years.On the basis of type, spirulina market share is segmented into Arthrospira Platensis and Arthrospira Maxima.
Arthrospira Maxima dominates the global Spirulina market and will be the dominant throughout the forecasted period.On the basis of application, the Spirulina market is categorised into Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others.Food & Beverages segment is likely to develop significantly over the period of time owing to fast growing food & beverage industry.On the basis of drug formulation, the spirulina market is bifurcated into Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent.
Powder segment is expected to account for the major market share & dominate the market growth over the forecast period.North America dominates the spirulina market in terms of market size over the forecast period, owing to rising health consciousness among people.
Hansen Holding A/S, Algenol Biofuels Inc., Dongtai City Spirulina Bio-engineering Co., Ltd., Prolgae, Parry Neutraceuticals, Sensient Technologies Corporation, DDW Inc., Algatec and Naturex S.A.Browse key industry insights from the report, “Spirulina Market Size By Type (ArthrospiraPlatensis and Arthrospira Maxima) By Application (Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others), By Drug Formulation (Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent)Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, China, India, Japan, Australia, Indonesia, Malaysia, South Korea, Brazil, Mexico, South Africa, Saudi Arabia, UAE, Kuwait), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020–2030” in detail along with the table of contents:Key Insights from the Spirulina Market Report:Asia Pacific is the fastest growing region in Spirulina market owing to the rising demand of spirulina from various industries such as cosmetics, food , healthcare and others and government initiatives to promote local spirulina production.The Food & Beverages segment dominates the market in terms of application and is expected to grow at a significant CAGR to maintain the lead till 2030.Some of the major players in the market are DIC Corporation, Cyanotech Corporation, Chr.
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
This report studies the global market size of Pressure Infusion Cuffs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pressure Infusion Cuffs in these regions.
This report also studies the global Pressure Infusion Cuffs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
Request a sample of this report@ https://www.orbisresearch.com/contacts/request-sample/2322852?utm_source=Mohit
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
AC Cossor & Son (Surgical)
Market size by End User
